KAUFFMAN ROBERT S.,TITEUX CYRIL JEAN CAMILLE,POLO RAMON,VAN HEESWIJK RUDOLF PETER GERHARD,BEUMONT MARIA GLORA,PICCHIO GASTON RAFAEL
申请号：
NZ60404509
公开号：
NZ604045A
申请日:
2009.09.24
申请国别(地区):
NZ
年份:
2014
代理人:
摘要：
604045 Disclosed is the use of one, two or all three of peginterferon and ribavirin with VX-950 in the manufacture of a pharmaceutical composition for treatment of Hepatitis C virus by administration in accordance with a therapeutic regimen comprising administration of peginterferon alpha-2a and ribavirin with VX-950 in an initial phase and administering peginterferon alpha-2a and ribavirin over a secondary phase, wherein the secondary phase occurs after the initial phase, and wherein VX-950 is administered in an amount of 1125 mg twice per day, peginterferon alpha-2a is administered in an amount of 180 micrograms per week and ribavirin is administered in an amount of 1000 to 1200 mg per day. Alternatively the secondary phase occurs after the initial phase, and wherein VX-950 is administered in an amount of 1125 mg twice per day, peginterferon alpha-2b is administered in an amount of 1.5 micrograms per kilogram of patient body weight per week and ribavirin is administered in an amount of 800 to 1200 mg per day.
